uniQure N.V.
QURE$1.55B
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaAMSTERDAM209 employees
Drugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Sep 30, 2026
28wMarket Overview
Stock performance and key metrics
QURE News
Catalyst Timeline
1 upcoming, 2 past
Drug Pipeline
AMT-191
Fabry Disease
rAAV2/5-hNAGLU
Sanfilippo Syndrome B
AMT-162
Amyotrophic Lateral Sclerosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
AMT-191 | Phase 2 | Fabry Disease | - | - |
rAAV2/5-hNAGLU | Phase 2 | Sanfilippo Syndrome B | - | - |
AMT-162 | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply